Loading...
•
Sep 30, 2021
Astria Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Key Takeaways
Astria Therapeutics reported a net loss of $7.9 million for the third quarter of 2021, with cash and cash equivalents totaling $131.8 million as of September 30, 2021. The company's operating plan is funded through 2023.
Cash and cash equivalents totaled $131.8 million as of September 30, 2021.
Net cash used in operating activities for the three months ended September 30, 2021, was $7.7 million.
Research and development expenses were $3.8 million for the three months ended September 30, 2021.
Net loss per share basic and diluted was $0.61 for the three months ended September 30, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...